OncoCyte
OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostic tests for cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in proprietary laboratory-developed tests, including DetermaRx for early-stage lung adenocarcinoma and DetermaIO, a gene expression-based test. Additionally, OncoCyte is advancing DetermaDx, a non-invasive blood test aimed at detecting lung cancer. The company emphasizes the importance of providing actionable information to physicians and patients during critical decision-making moments in lung cancer care. Through strategic collaborations, such as with Guardian Research Network, OncoCyte seeks to enhance patient recruitment and streamline regulatory processes, ultimately aiming to improve patient outcomes and reduce healthcare costs.
Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.